Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | patients receiving Atrovent® |
| |
| Cronic Obstructive Pulmonary Disease | patients receiving Ventilat® |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atrovent® | Drug |
| ||
| Ventilat® |
| Measure | Description | Time Frame |
|---|---|---|
| Change in overall severity of the clinical picture rated on a 4-point scale | Up to 6 months after first study drug administration | |
| Investigator assessment of improvement of thec linical picture rated on a 6-point symptom profile | Up to 6 months after first study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of efficacy by investigator on a 4-point scale | Up to 6 months after first study drug administration | |
| Assessment of efficacy by patient on a 4-point scale | Up to 6 months after first study drug administration |
Not provided
Inclusion Criteria:
Patients of both genders older than 40 years, who suffer from moderate or severe Chronic Obstructive Pulmonary Disease
Only patients who showed following diagnosis parameters were to be considered for inclusion
Exclusion Criteria:
• Contraindications listed in the Instructions for Use/Summary of Product Characteristics
Not provided
Not provided
Not provided
Patients with chronic obstructive airways disease recruited by registered pneumologists
Not provided
Not provided
Not provided
Not provided
|
| Assessment of tolerability by investigator on a 4-point scale | Up to 6 months after first study drug administration |
| Assessment of tolerability by patient on a 4-point scale | Up to 6 months after first study drug administration |
| Number of patients with adverse drug reactions | Up to 6 months after first study drug administration |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D009241 | Ipratropium |
| C017590 | oxitropium |
| ID | Term |
|---|---|
| D001286 | Atropine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
| D009930 | Organic Chemicals |
| D001533 | Belladonna Alkaloids |
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
Not provided
Not provided